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early, yielding mediastinal lymph node me-
tastases or distant metastases (generally in
the liver or in the brain) at the time of
diagnosis.
Correct preoperative diagnosis of neu-
roendocrine carcinoma of the lung (and
also of LCNC) is really difficult to obtain
either by bronchoscopy or by transthoracic
biopsy; in the case of clinical N2 neuroen-
docrine carcinoma, a surgical approach can
be considered, because these tumors do not
respond to neoadjuvant therapy.4 This
could be appropriate in case of bronchial
carcinoid, but not in case of LCNC. For
these tumors, I believe, neoadjuvant treat-
ment is mandatory because of their aggres-
sive biologic behavior.
In this study Takei and colleagues1
pointed out the importance of the immuno-
histochemical assessment, with the detec-
tion of chromogranin A staining in neo-
plastic cells. We must remember that
LCNCs, because they are neuroendocrine
carcinomas, express somatostatin recep-
tors, which can be easily detected in vitro
by reverse transcriptase polymerase chain
reaction.5 In vivo expression of these re-
ceptors is provided by indium 111–tagged
diethylenetriaminepentaacetic acid pente-
treotide (OctreoScan, OCT) scintigra-
phy.6,7 This procedure is widely accepted
both in the preoperative evaluation of neu-
roendocrine carcinoma, because of its ef-
fectiveness in detecting mediastinal or dis-
tant metastases with high sensitivity, and in
follow-up for early detection of tumor re-
currences or distant metastases.8 In case of
positive OCT scintigraphy result, therapy
with octreotide (new generation somatosta-
tin analog) might be considered, alone or in
association with chemotherapy. I believe
that such an important biologic concept
might be considered in the correct multi-
disciplinary treatment of LCNC of the
lung. Octreotide has been proved to be
effective in controlling metastatic growth,
well tolerated by the patient, and without
important side effects.8,9
In conclusion, I congratulate Takei and
colleagues1 for this excellent article on
such a difficult matter. I recommend the
use of OCT scintigraphy in the preopera-
tive evaluation of these patients and in their
follow-up. Furthermore the use of oct-
reotide (in the case of positive results of
OCT scintigraphy), in association with tra-
ditional adjuvant therapy, might be consid-
ered to reduce the risk of tumor recurrence
or distant metastases.
Pier Luigi Filosso, MD
University of Torino Italy
San Giovanni Battista Hospital
Department of Thoracic Surgery
Via Genova, 3
10126 Torino, Italy
References
1. Takei H, Asamura H, Maeshima A, Suzuki
K, Kondo H, Niki T, et al. Large cell neu-
roendocrine carcinoma of the lung: a clini-
copathologic study of eighty-seven cases.
J Thorac Cardiovasc Surg. 2002;124:285-
92.
2. World Health Organization. Histological
typing of lung and pleural tumours. 3rd ed.
Geneva: The Organization; 1999.
3. Travis WD, Colby TV, Corrin B, Shimosato
Y, Brambilla E. Histological typing of lung
and pleural tumours. 3rd ed. Berlin:
Springer Verlag; 1999.
4. Martini N, Zaman MB, Bains MS, Burt ME,
McCormack PM, Rusch VW, et al. Treat-
ment and prognosis in bronchial carcinoids
involving regional lymph nodes. J Thorac
Cardiovasc Surg. 1994;107:1-6.
5. Papotti M, Croce S, Bello M, Bongiovanni M,
Allia E, Schindler M, et al. Expression of
somatostatin receptor types 2, 3 and 5 in bi-
opsies and surgical specimens of human lung
tumours. Vircows Arch. 2001;439:787-97.
6. Kwekkeboom DJ, Kho GS, Lamberts SW,
Reubi JC, Laissue JA, Krenning EP. The
value of octreotide scintigraphy in patients
with lung cancer. Eur J Nucl Med. 1994;21:
1106-13.
7. Musi M, Carbone RG, Bertocchi C, Cantalupi
DP, Michetti G, Pugliese C, et al. Bronchial
carcinoid tumours: a study on clinicopatho-
logical features and role of octreotide scintig-
raphy. Lung Cancer. 1998;22:97-102.
8. Filosso PL, Ruffini E, Oliaro A, Papalia E,
Donati G, Rena O. Long-term survival of
atypical bronchial carcinoid with liver me-
tastases, treated with octreotide. Eur J Car-
diothorac Surg. 2002;21:913-7.
9. O’Byrne KJ, Schally AV, Thomas A, Car-
ney DN, Steward WP. Somatostatin, its re-
ceptors and analogs, in lung cancer. Chemo-
therapy. 2001;47:78-108.
doi:10.1067/mtc.2003.321
Reply to the Editor:
We appreciate the thoughtful comments by
Filosso on our recent article1 describing the
clinicopathologic aspects of large cell neu-
roendocrine carcinoma (LCNC) of the
lung.
The histologic type of LCNC of the
lung has been included as the subtype of
large cell carcinoma in the revised World
Health Organization classification of lung
and pleural tumors in 1999.2 The clinico-
pathologic features, however, have not
been described in detail. Especially little is
known about the response of LCNC to the
chemotherapy and radiotherapy. Consider-
ing the analogy of LCNC to the small cell
histologic type, a multimodal therapeutic
approach might be expected to be promis-
ing.
As Filosso pointed out, we also have a
great interest in the expression of soma-
tostatin receptors in LCNC. If these recep-
tors are expressed frequently in LCNC, oc-
treotide scintigraphy with somatostatin
analog (OctreoScan) would reasonably be
of great utility in the preoperative evalua-
tion of extent of disease of LCNC. Indeed,
carcinoid tumor and small cell carcinoma
have already been shown to be well ana-
lyzed by octreotide scintigraphy.3,4 As for
LCNC, however, according to a report by
Jiang and colleagues,5 only 9 (40.9%) of 22
cases were shown to stain positively for
somatostatin, and these tumor cells do not
necessarily express somatostatin receptors.
Whether octreotide scintigraphy can be
used depends on the rate of expression of
somatostatin receptors. At present no data
are available on the expression of soma-
tostatin receptors in LCNC.
Furthermore, the preoperative establish-
ment of a histologic diagnosis of LCNC is
crucial in planning the LCNC-specific
treatment strategy. However, it is actually
quite difficult to get the histologic or cyto-
logic diagnosis of LCNC simply by the
evaluation of tiny preoperative biopsy
specimen. Novel LCNC-specific markers
(“immunohistochemically detectable”)
must be sought; such markers would easily
enable the histologic diagnosis of LCNC.
Again, we pointed out that LCNC
should be recognized as one of the poorest
prognostic subgroups in lung cancer, and
novel therapeutic approaches should be es-
tablished. Further accumulation of clinico-
pathologic characteristics, especially the
response to nonsurgical treatment, is the
most important issue. The histologic clas-
sification of lung tumors with neuroendo-
crine phenotype also seems to need further
revision in the near future.
Hidefumi Takei, MD
Hisao Asamura, MD
Yoshihiro Matsuno, MD
National Cancer Center Hospital
Tokyo, Japan
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Tuberculous aneurysms of the aorta
To the Editor:
We read with interest the brief report on
tubercular aneurysm of the descending tho-
racic aorta published in February 2002 is-
sue of the Journal.1 The reported case
highlights the rare nature of the condition
and the catastrophic presentation in a pa-
tient receiving antitubercular drugs for dis-
seminated tuberculosis.
We recently published our group’s ex-
perience with 5 cases of tuberculous
pseudoaneurysms of the aorta successfully
treated at our unit during a 3-year period
between 1997 and 1999.2 The sites of in-
volvement in these 5 patients included the
ascending aorta, distal aortic arch, proxi-
mal descending thoracic aorta, distal de-
scending thoracic aorta, and infrarenal ab-
dominal aorta, thus indicating that any
segment of the aorta may be involved in an
appropriate clinical setting. All these pa-
tients had received antitubercular drugs in
the past and were first seen with sudden
deterioration in clinical status. Because tu-
berculosis is not uncommon in our part of
the world, we promptly suspected the di-
agnosis, leading to successful management.
Since then we have successfully managed 3
more cases of pseudoaneurysm of the
aorta. Two of these lesions occurred in the
infrarenal aorta, and 1 occurred in the de-
scending thoracic aorta. Thus in the past 5
years we have come across 8 patients with
this condition. This diagnosis is therefore
not that uncommon if the diagnosis is sus-
pected in the appropriate clinical setting.
A striking feature in all these cases
was that the aneurysm was saccular in
nature. This is probably because most of
these lesions are pseudoaneurysms. This
is important, because pseudoaneurysm of
the aorta in a patient with active or
treated tuberculosis may point to the di-
agnosis.
Before our report, only 88 cases of this
condition had been reported in the English-
language medical literature.2 We believe
that as the incidences of drug-resistant and
human immunodeficiency virus–associated
infection rise, the entity will be encoun-
tered more frequently.
Because the condition may present with
catastrophic symptoms and signs, ready an-
ticipation of the diagnosis is required to
achieve an optimal outcome. Histopatho-
logic examination and culture of the tissue
from the aneurysm wall should be a rou-
tine. This may help to identify and institute
the correct drug treatment in such cases.
Sachin Talwar, MCh
Shiv Kumar Choudhary, MCh
Cardiothoracic Centre
All India Institute of Medical Sciences
New Delhi, India
References
1. Hatem CM, Kantis GA, Christoforou D,
Gold JP, Plestis KA. Tuberculous aneurysm
of the descending thoracic aorta. J Thorac
Cardiovasc Surg. 2002;123:373-3.
2. Choudhary SK, Bhan A, Talwar S, Goyal
M, Sharma S, Venugopal P. Tubercular
pseudoaneurysms of aorta. Ann Thorac
Surg. 2001;72:1239-44.
doi:10.1067/mtc.2003.271
Letters to the Editor
1184 The Journal of Thoracic and Cardiovascular Surgery ● May 2003
